Previous 10 | Next 10 |
Genetic testing is the study of the cells and tissues contained in the gene to get a better understanding of genetic disorders such as like cancer etc. New genetic testing technologies, together with increasing efficiency and accuracy are providing lucrative growth opportunities for the geneti...
SAN FRANCISCO , Nov. 21, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Shelly Guyer , chief financial officer of Invitae, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on W...
Editors' Note: This is the transcript of the podcast we published last week on Invitae (NVTA). We hope you enjoy. Daniel Shvartsman: Welcome to the Razor's Edge. I'm Daniel Shvartsman. I'm joined by Seeking Alpha author Akram's Razor on this show. Each episode we take an investing id...
PHILADELPHIA , Nov. 15, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced Invitae Discover , a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the...
The following slide deck was published by Invitae Corporation in conjunction with their 2019 Q3 earnings Read more ...
Quick Take Invitae ( NVTA ) said that it has agreed to acquire Clear Genetics for approximately $50 million in cash and stock. Clear Genetics has developed a healthcare chatbot system that provides genetic testing information to patients and counselors. With the deal, NVTA is continuin...
SAN FRANCISCO , Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Us...
by Daniel Shvartsman Listen to or subscribe to The Investing Edge on these podcast platforms: Apple Podcasts Spotify Google Play Stitcher Seeking Alpha On this week's The Razor's Edge, we discussed Akram's Razor's recent short case on Invitae (NVTA). If...
BURLINGTON, Vt ., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks...
Image source: The Motley Fool. Invitae Corp (NYSE: NVTA) Q3 2019 Earnings Call Nov 6, 2019 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...